Nasal In Situ Gel: Novel Approach for Nasal Drug Delivery
Nasal delivery is an alternative to oral or parenteral administration due to certain limitations such as absorption of the drug, drug targeting to particular organs can cause a problem for administration through oral route. The nasal route has also been successfully used for bypassing the blood-brain barrier and afterword delivering drug molecules to the central nervous system. Also, lag time related to oral drug delivery is reduces by this route and offers noninvasiveness, self-medication, patient comfort, and patient compliance. Extend drug delivery can be attained by different new dosage forms like in situ gel. In situ formulations are drug delivery systems. The in-situ gelling system is a process in which the solution forms of a gel before administration in the body, but once administrated, it undergoes gelation in-situ, to form a gel. In situ gelling system becomes very popular nowadays because of their several advantages over conventional drug delivery systems like a sustained and prolonged release of a drug, reduced Frequency of administration, improved patient compliance and comfort. Approaches towards the various formulation of in-situ gel concerning temperature, pH, and physicochemical conditions. The in situ gel-forming polymeric formulations offer several advantages like sustained and prolonged action reduced Frequency of administration, in comparison to conventional drug delivery systems. From a manufacturing point of view, the production of such systems is less complex and thus lowers the investment and manufacturing cost. Various evaluation parameters are considered during the preparation of In-Situ gel.
Keywords: Nasal Drug Delivery, In Situ gel, gelation, polymers, etc
2. Chand P, Gnanarajan G, Kothiyal P. In situ gel : A Review. Indian J Pharm Biol Res ( IJPBR). 2016;4(2):11–9.
3. Karavasili C, Fatouros DG. Smart materials: In situ gel-forming systems for nasal delivery. Drug Discov Today. 2016; 21(1):157–66.
4. Kaur P, Garg T, Rath G, Goyal AK. In situ nasal gel drug delivery: A novel approach for brain targeting through the mucosal membrane. Artif Cells, Nanomedicine Biotechnol. 2016; 44(4):1167–76.
5. J.U.Kute, A. B. Darekar RBS. in Situ Gel-Novel Approach for Nasal Delivery. World J Pharm Pharm Sci. 2014; 3(i):187–203.
6. Prasanth V V, Grace D, Parambi T, Vinod B, Mathew ST, Sheri PS. in-Situ Nasal Gels – an Update. 2016; 5(11):591–612.
7. Ban MM, Chakote VR, Dhembre GN, Rajguru JR, Joshi DA. in-Situ Gel for Nasal Drug Delivery Original Research Article in-Situ Gel for Nasal Drug Delivery. 2018; (March).
8. Salunke SR, Patil SB. Ion activated in situ gel of gellan gum containing salbutamol sulphate for nasal administration. Int J Biol Macromol [Internet]. 2016; 87(February):41–7. Available from: http://dx.doi.org/10.1016/j.ijbiomac.2016.02.044
9. Devi R, Chaudhary A, Pandit V. Mucoadhesive insitu nasal gel-A novel approach. J Adv Drug Deliv. 2014; 1(6).
10. Vibha B. In Situ Gel Nasal Drug Delivery System – A Review. Indian J Pharma Sci. 2014; 4(3):577–80.
11. Nirmal HB, Bakliwal SR, Pawar SP, College PSGVPM. In-Situ gel : New trends in Controlled and Sustained Drug Delivery System. 2010; 2(2):1398–408.
12. Nirmal HB, Bakliwal SR, Pawar SP. In-Situ gel: New trends in controlled and sustained drug delivery system. Int J PharmTech Res. 2010; 2(2):1398–408.
13. Xie H, Li L, Sun Y, Wang Y, Gao S, Tian Y, et al. An available strategy for nasal brain transport of nanocomposite based on PAMAM dendrimers via in situ gel. Nanomaterials. 2019; 9(2).
14. Tao T, Zhao Y, Yue P, Dong WX, Chen QH. Preparation of huperzine A nasal in situ gel and evaluation of its brain targeting following intranasal administration. Yaoxue Xuebao. 2006; 41(11):1104–10.
15. Shinde J V, Mali KK, Dias RJ, Havaldar VD, Mahajan NS. Insitu Mucoadhesive Nasal Gels of Metoclopramide Hydrochloride : Preformulation and Formulation Studies. J Pharm Res. 2008; 1(1):88–96.
16. Mahajan HS, Gattani S. In situ gels of Metoclopramide Hydrochloride for intranasal 4delivery: In vitro evaluation and in vivo pharmacokinetic study in rabbits. Drug Deliv. 2010; 17(1):19–27.
17. Khan S, Patil K, Bobade N, Yeole P, Gaikwad R. Formulation of intranasal mucoadhesive temperature-mediated in situ gel containing ropinirole and evaluation of brain targeting efficiency in rats. J Drug Target. 2010; 18(3):223–34.
18. Mahakalkar NG, Upadhye KP. Research Article Zolmitriptan Nasal. 2013; 22(2):206–13.
19. Chen X, Zhi F, Jia X, Zhang X, Ambardekar R, Meng Z, et al. Enhanced brain targeting of curcumin by intranasal administration of a thermosensitive poloxamer hydrogel. J Pharm Pharmacol. 2013; 65(6):807–16.
20. Galgatte UC, Kumbhar AB, Chaudhari PD. Development of in situ gel for nasal delivery: Design, optimization, in vitro and in vivo evaluation. Drug Deliv. 2014; 21(1):62–73.
21. Sharma S, Lohan S, Murthy RSR. Formulation and characterization of intranasal mucoadhesive nanoparticulates and thermo-reversible gel of levodopa for brain delivery. Drug Dev Ind Pharm. 2014; 40(7):869–78.
22. Kaur P, Garg T, Vaidya B, Prakash A, Rath G, Goyal AK. Brain delivery of intranasal in situ gel of nanoparticulated polymeric carriers containing antidepressant drug: Behavioral and biochemical assessment. J Drug Target [Internet]. 2015; 23(3):275–86. Available from: http://dx.doi.org/10.3109/1061186X.2014.994097
23. Naik A, Nair H. Formulation and evaluation of thermosensitive biogels for nose to brain delivery of doxepin. Biomed Res Int. 2014;2014.
24. Verma P, Prashar N, Chaudhary H. Nasal (In-situ) gel (Phenylepherine HCl) for allergic rhinitis congestion treatment: development and characterization. Am J PharmTech Res. 2016; (July).
25. Jagdale S, Shewale N, Kuchekar BS. Optimization of Thermoreversible in Situ Nasal Gel of Timolol Maleate. Scientifica (Cairo). 2016;2016.
26. Rao M, Agrawal DK, Shirsath C. Thermoreversible mucoadhesive in situ nasal gel for treatment of Parkinson’s disease. Drug Dev Ind Pharm. 2017; 43(1):142–50.
27. Lungare S, Bowen J, Badhan R. Development and Evaluation of a Novel Intranasal Spray for the Delivery of Amantadine. J Pharm Sci [Internet]. 2016; 105(3):1209–20. Available from: http://dx.doi.org/10.1016/j.xphs.2015.12.016
28. Khandagale PM, Rokade MM, Phadtare DG. Formulation Development and Evaluation of Nasal In-Situ Gel of Hydrocortisone . Asian J Pharm Technol. 2018; 8(2):92.
29. Wang Y, Jiang S, Wang H, Bie H. A mucoadhesive, thermoreversible in situ nasal gel of geniposide for neurodegenerative diseases. PLoS One. 2017; 12(12):1–17.
30. Shah V, Sharma M, Pandya R, Parikh RK, Bharatiya B, Shukla A, et al. Quality by Design approach for an in situ gelling microemulsion of Lorazepam via intranasal route. Mater Sci Eng C [Internet]. 2017; 75:1231–41. Available from: http://dx.doi.org/10.1016/j.msec.2017.03.002
31. Pathan IB, Mene H, Bairagi S. Quality by design (QbD) approach to formulate in situ gelling system for nose to brain delivery of Fluoxetine hydrochloride: Ex-vivo and In-vivo study. Ars Pharm. 2017; 58(3):107–14.
32. Abouhussein DMN, Khattab A, Bayoumi NA, Mahmoud AF, Sakr TM. Brain targeted rivastigmine mucoadhesive thermosensitive In situ gel: Optimization, in vitro evaluation, radiolabeling, in vivo pharmacokinetics and biodistribution. J Drug Deliv Sci Technol [Internet]. 2018; 43:129–40. Available from: https://doi.org/10.1016/j.jddst.2017.09.021
33. Fatouh AM, Elshafeey AH, Abdelbary A. Agomelatine-based in situ gels for brain targeting via the nasal route: Statistical optimization, in vitro, and in vivo evaluation. Drug Deliv [Internet]. 2017; 24(1):1077–85. Available from: https://doi.org/10.1080/10717544.2017.1357148
34. Pathan IB, More B. Formulation and characterization of intra nasal delivery of nortriptyline hydrochloride thermoreversible gelling system in treatment of depression. Acta Pharm Sci. 2017; 55(2):35–44.
35. Salatin S, Barar J, Barzegar-Jalali M, Adibkia K, Jelvehgari M. Thermosensitive in situ nanocomposite of rivastigmine hydrogen tartrate as an intranasal delivery system: Development, characterization, ex vivo permeation and cellular studies. Colloids Surfaces B Biointerfaces [Internet]. 2017; 159:629–38. Available from: http://dx.doi.org/10.1016/j.colsurfb.2017.08.031
36. Sherje AP, Londhe V. Development and Evaluation of pH-Responsive Cyclodextrin-Based in situ Gel of Paliperidone for Intranasal Delivery. AAPS PharmSciTech. 2018; 19(1):384–94.
37. Durgapal S, Rana M, Mukhopadhyay S, Rana AJ, Goswami L, Joshi S. Formulation and Evaluation of in-Situ Nasal Gel of Montelukast Sodium for the Effective Treatment of Asthma. Int J Pharm Sci Res. 2018; 9(7):2792–9.
38. Patil RP, Pawara DD, Gudewar CS, Tekade AR. Nanostructured cubosomes in an in situ nasal gel system: an alternative approach for the controlled delivery of donepezil HCl to brain. J Liposome Res [Internet]. 2019; 29(3):264–73. Available from: http://dx.doi.org/10.1080/08982104.2018.1552703
39. V SCM, P AK, Manjunath K, Kulkarni S V. Development Characterization and Evaluation of Nasal in situ Gel containing Anti-Asthmatic Drug. 2019; 7(3):3001–6.
40. Karpagavalli L, Gopalasrsatheeskumar K, Narayanan N, Maheswaran A, Raj AI, Priya JH. Formulation and Evaluation of Zolpidem Nasal in Situ Gel. World J Pharm Res. 2017; 6(2).
41. Rajput AP, Butani SB. Resveratrol anchored nanostructured lipid carrier loaded in situ gel via nasal route: Formulation, optimization and in vivo characterization. J Drug Deliv Sci Technol [Internet]. 2019; 51(February):214–23. Available from: https://doi.org/10.1016/j.jddst.2019.01.040
42. Hao J, Zhao J, Zhang S, Tong T, Zhuang Q, Jin K, et al. Colloids and Surfaces B : Biointerfaces Fabrication of an ionic-sensitive in situ gel loaded with resveratrol nanosuspensions intended for direct nose-to-brain delivery. Colloids Surfaces B Biointerfaces [Internet]. 2016; 147:376–86. Available from: http://dx.doi.org/10.1016/j.colsurfb.2016.08.011
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).